Iovance Biotherapeutics

$47.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-0.21%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IOVA and other stocks, options, and ETFs commission-free!

About IOVA

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. The listed name for IOVA is Iovance Biotherapeutics, Inc. Common Stock.

CEO

Maria Fardis

Employees

148

Headquarters

San Carlos, California

Founded

2007

Market Cap

7.16B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.29M

High Today

$48.86

Low Today

$47.03

Open Price

$47.94

Volume

1.08M

52 Week High

$54.21

52 Week Low

$18.70

Collections

Analyst Ratings

83%

of 12 ratings

Buy

83%

Hold

17%

Sell

IOVA Earnings

-$0.55

-$0.37

-$0.18

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 23, After Hours